What changed: Gastric and gastro-oesophageal junction adenocarcinoma
Every dated change on the records linked to Gastric and gastro-oesophageal junction adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Milestone9This record1
September 2026 · 1
2025 · 2
- 2025MilestoneGastric and gastro-oesophageal junction adenocarcinomaESOPEC trial reported perioperative FLOT superior to neoadjuvant CROSS for resectable oesophageal/GEJ adenocarcinoma
Median overall survival 66 versus 37 months.
- 2025MilestoneGastric and gastro-oesophageal junction adenocarcinomaMATTERHORN trial showed perioperative durvalumab plus FLOT improves event-free survival over FLOT alone in resectable gastric/GEJ adenocarcinoma
Published in NEJM 2025;393:217-30.
2024 · 1
2021 · 3
- 2021MilestoneGastric and gastro-oesophageal junction adenocarcinomaFDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for HER2-positive gastric/GEJ adenocarcinoma after prior trastuzumab
Approved 15 January 2021, based on DESTINY-Gastric01.
- 2021MilestoneGastric and gastro-oesophageal junction adenocarcinomaFDA approved nivolumab plus chemotherapy first line for advanced gastric, GEJ and oesophageal adenocarcinoma regardless of PD-L1 status
Approved 16 April 2021, based on CheckMate 649.
- 2021MilestoneGastric and gastro-oesophageal junction adenocarcinomaFDA granted accelerated approval to pembrolizumab plus trastuzumab plus chemotherapy for first-line HER2-positive, PD-L1 CPS 1 or above gastric/GEJ adenocarcinoma
Approved 5 May 2021 based on KEYNOTE-811; converted to full approval in March 2025.